Serum MMP3 Correlates with Renal Function Tests and Insulin Resistance Parameters in Patients with End-stage Renal Disease
Article Sidebar
Main Article Content
Abstract
End-stage renal disease (ESRD) is associated with changes in serum biomarkers. However, except for the renal function test, there is no definite useful biomarker correlated with the disease and its consequences, such as insulin resistance (IR). In the present study, matrix metalloproteinases-3 (MMP3) and its inhibitor, the tissue inhibitor of metalloproteinase-1 (TIMP1) were examined and correlated with IR parameters. MMP3, TIMP1, renal function tests, and IR parameters were measured in 60 ESRD patients and the results were compared with thirty healthy controls. After controlling for all cofounders, ESRD patients showed a substantial rise in serum MMP3, glucose, insulin, and beta-cell function percentage compared to the control group. While the patients had a lower insulin sensitivity percentage when compared to the controls. TIMP1, insulin/glucose ratio, and insulin resistance index did not vary significantly across groups. MMP3 had a strong relationship with serum creatinine, urea, and eGFR. TIMP1 had a strong relationship with height and weight. High serum MMP3 is associated with increased renal function tests and with changes in the IR parameters in ESRD patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Transfer Statement
The copyright of this article is transferred to Current Applied Science and Technology journal with effect if and when the article is accepted for publication. The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, electronic form (offline, online) or any other reproductions of similar nature.
The author warrants that this contribution is original and that he/she has full power to make this grant. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors.
Here is the link for download: Copyright transfer form.pdf
References
Ricci, Z. and Romagnoli, S., 2018. Acute kidney injury: diagnosis and classification in adults and children. Contributions to Nephrology, 193, 1-12, https://doi.org/10.1159/000484956.
Koza, Y., 2016. Acute kidney injury: current concepts and new insights. Journal of Injury and Violence Research, 8(1), 58-62, https://doi.org/10.5249/jivr.v8i1.610.
Parving, H.H., Andersen, A.R., Smidt, U.M., Christiansen, J.S., Oxenbøll, B. and Svendsen, P.A., 1983. Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes, 32(Supplement 2), 83-87, https://doi.org/10.2337/diab.32.2.s83.
Dai, L., Golembiewska, E., Lindholm, B. and Stenvinkel, P., 2017. End-stage renal disease, inflammation and cardiovascular outcomes. Contributions to Nephrology, 191, 32-43, https://doi.org/10.1159/000479254.
Benjamin, O. and Lappin, S.L., 2022. End-Stage Renal Disease. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, pp. 23-30.
Paiva, K.B. and Granjeiro, J.M., 2017. Matrix metalloproteinases in bone resorption, remodeling, and repair. Progress in Molecular Biology and Translational Science, 148, 203-303, https://doi.org/10.1016/bs.pmbts.2017.05.001.
Coskun, Z.M., Beydogan A.B., Yanar, K., Atukeren, P. and Bolkent, S., 2021. Oxidative stress and inflammatory response of ghrelin on myocardial and aortic tissues in insulin-resistant rats. Journal of Pharmacy and Pharmacology, 73(5), 692-699, https://doi.org/10.1093/jpp/rgab024.
Gimeno, A., Beltrán-Debón, R., Mulero, M., Pujadas, G. and Garcia-Vallvé, S., 2020. Understanding the variability of the S1′ pocket to improve matrix metalloproteinase inhibitor selectivity profiles. Drug Discovery Today, 25(1), 38-57, https://doi.org/10.1016/j.drudis.2019.07.013.
Chen, J.-J., Huang, J.F., Du, W.-X. and Tong, P.J., 2014. Expression and significance of MMP3 in synovium of knee joint at different stage in osteoarthritis patients. Asian Pacific Journal of Tropical Medicine, 7(4), 297-300, https://doi.org/10.1016/S1995-7645(14)60042-0.
Taha, E.A., Sogawa, C., Okusha, Y., Kawai, H., Oo, M.W., Elseoudi, A., Lu, Y., Nagatsuka, H., Kubota, S., Satoh, A., Okamoto, K. and Eguchi, T., 2020. Knockout of MMP3 weakens solid tumor organoids and cancer extracellular vesicles. Cancers, 12(5), https://doi.org/10.3390/cancers12051260.
McCawley, L.J., Wright, J., LaFleur, B.J., Crawford, H.C. and Matrisian, L.M., 2008. Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. The American Journal of Pathology, 173(5), 1528-1539, https://doi.org/10.2353/ajpath.2008.080132.
Eguchi, T., Calderwood, S.K., Takigawa, M., Kubota, S. and Kozaki, K.I., 2017. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins. Journal of Cellular Biochemistry, 118(1), 43-51, https://doi.org/10.1002/jcb.25607.
Galehdari, H., Negahdari, S., Kesmati, M., Rezaie, A. and Shariati, G.J., 2016. Effect of the herbal mixture composed of Aloe vera, Henna, Adiantum capillus-veneris, and Myrrha on wound healing in streptozotocin-induced diabetic rats. BMC Complementary Alternative Medicine, 16(1), https://doi.org/10.1186/s12906-016-1359-7.
Xu, Q., Gai, P.Y., Lv, H.L., Li, G.R. and Liu, X.Y., 2016. Association of MMP3 genotype with susceptibility to frozen shoulder: a case-control study in a Chinese Han population. Genetic Molecular Research, 15(1), https://doi.org/10.4238/gmr.15017228.
Hamze, A.B., Wei, S., Bahudhanapati, H., Kota, S., Acharya, K.R. and Brew, K., 2007. Constraining specificity in the N‐domain of tissue inhibitor of metalloproteinases‐1; gelatinase‐selective inhibitors. Protein Science, 16(9), 1905-1913, https://doi.org/10.1110/ps.072978507.
Parrish, A.R., 2017. Matrix metalloproteinases in kidney disease: role in pathogenesis and potential as a therapeutic target. Progress in Molecular Biology and Translational Science, 148, 31-65, https://doi.org/10.1016/bs.pmbts.2017.03.001.
Li, K., Tay, F.R. and Yiu, C.K.Y., 2020. The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacology Therapeutics, 207, https://doi.org/10.1016/j.pharmthera.2019.107465.
Adamson, A., Ghoreschi, K., Rittler, M., Chen, Q., Sun, H.-W., Vahedi, G., Kanno, Y., Stetler-Stevenson, W.G., O’Shea, J.J. and Laurence, A., 2013. Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene. PLoS One, 8(3), https://doi.org/10.1371/journal.pone.0059367.
Stetler-Stevenson, W.G., 2008. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Science Signaling, 1(27), https://doi.org/10.1126/scisignal.127re6.
Freeman, A.M. and Pennings, N., 2021. Insulin resistance. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, pp. 44-50.
Levey, A.S., Coresh, J., Greene, T., Marsh, J., Stevens, L.A., Kusek, J.W. and Van Lente, F., 2007. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clinical Chemistry, 53(4), 766-772, https://doi.org/10.1373/clinchem.2006.077180.
Kwakernaak, A.J., Zelle, D.M., Bakker, S.J.L. and Navis, G., 2013. Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index. Journal of the American Society of Nephrology, 24(6), 987-994, https://doi.org/10.1681/ASN.2012050460.
Preston, G.A., Barrett, C.V., Alcorta, D.A., Hogan, S.L., Dinwiddie, L., Jennette, J.C. and Falk, R.J., 2002. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron, 92(4), 817-823, https://doi.org/10.1159/000065464.
Kowluru, R.A., Zhong, Q. and Santos, J.M., 2012. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opinion on Investigational Drugs, 21(6), 797-805, https://doi.org/10.1517/13543784.2012.681043.
Zakiyanov, O., Kalousová, M., Zima, T. and Tesař, V., 2019. Matrix metalloproteinases in renal diseases: a critical appraisal. Kidney and Blood Pressure Research, 44(3), 298-330, https://doi.org/10.1159/000499876.
Robert, S., Gicquel, T., Bodin, A., Fautrel, A., Barreto, E., Victoni, T., Lagente, V and Boichot, E., 2019. Influence of inflammasome pathway activation in macrophages on the matrix metalloproteinase expression of human hepatic stellate cells. International Immunopharmacology, 72, 12-20, https://doi.org/10.1016/j.intimp.2019.03.060.
Akiyama, K., Shikata, K., Sugimoto, H., Matsuda, M., Shikata, Y., Fujimoto, N., Obata, K., Matsui, H. and Makino, H., 1997. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Research Communication Molecular Pathology Pharmacology, 95(2), 115-128.
Chou, F.-P., Chu, S.-C., Cheng, M.-C., Yang, S.-F., Cheung, W.-N., Chiou, H.-L. and Hsieh, Y.S., 2002. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clinical Biochemistry, 35(5), 383-388, https://doi.org/10.1016/S0009-9120(02)00331-4.
Rabkin, R., Ryan, M.P. and Duckworth, W.C., 1984. The renal metabolism of insulin. Diabetologia, 27(3), 351-357, https://doi.org/10.1007/BF00304849.
Deger, S.M., Hewlett, J.R., Gamboa, J., Ellis, C.D., Hung, A.M., Siew, E.D., Mamnungu, C., Sha, F., Bian, A. Stewart, T.G., Abumrad, N.N. and Ikizler, T.A., 2018. Insulin resistance is a significant determinant of sarcopenia in advanced kidney disease. American Journal of Physiology-Endocrinology and Metabolism, 315(6), E1108-E1120, https://doi.org/10.1152/ajpendo.00070.2018.
Wang, X.H., and Mitch, W.E., 2014. Mechanisms of muscle wasting in chronic kidney disease. National Review in Nephrology, 10(9), 504-516, https://doi.org/10.1038/nrneph.2014.112.
Hung, A.M., and Ikizler, T.A., 2011. Factors determining insulin resistance in chronic hemodialysis patients. Hemodialysis, 171, 127-134, https://doi.org/10.1159/000327177.
Fortes, P.C., de Moraes, T.P., Mendes, J.G., Stinghen, A.E., Ribeiro, S.C. and Pecoits-Filho, R., 2009. Insulin resistance and glucose homeostasis in peritoneal dialysis. Peritoneal Dialysis International, 29(Suppl.2), S145-S148.
Pham, H., Utzschneider, K.M. and de Boer, I.H., 2011. Measurement of insulin resistance in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 20(6), 640-646, https://doi.org/10.1097/MNH.0b013e32834b23c1.
Fliser, D., Kielstein, J.T. and Menne, J., 2006. Insulin resistance and renal disease. Obesity and the Kidney, 151, 203-211, https://doi.org/10.1159/000095330.
Allegra, V., Mengozzi, G., Martimbianco, L. and Vasile, A., 1990. Glucose-induced insulin secretion in uremia: effects of aminophylline infusion and glucose loads. Kidney international, 38(6), 1146-1150, https://doi.org/10.1038/ki.1990.325.
Trirogoff, M.L., Shintani, A., Himmelfarb, J. and Ikizler, T.A., 2007. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3–4 chronic kidney disease patients. The American Journal of Clinical Nutrition, 86(6), 1642-1648. https://doi.org/10.1093/ajcn/86.5.1642.
Lee, M.P.S. and Sweeney, G., 2006. Insulin increases gelatinase activity in rat glomerular mesangial cells via ERK‐and PI‐3 kinase‐dependent signalling. Diabetes, Obesity and Metabolism, 8(3), 281-288, https://doi.org/10.1111/j.1463-1326.2005.00502.x.
Boden, G., Song, W., Pashko, L. and Kresge, K., 2008. In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. Diabetes, 57(2), 476-483, https://doi.org/10.2337/db07-1261.
Boden, G., Song, W., Kresge, K., Mozzoli, M. and Cheung, P., 2008. Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. American Journal of Physiology-Endocrinology and Metabolism, 295(3), E692-E697, https://doi.org/10.1152/ajpendo.90370.2008.
Berg, G.A. and Miksztowicz, V., 2015. Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes. Metalloproteinases in Medicine. 2, 51-59, https://doi.org/10.2147/MNM.S88993.
Suzuki, D., Miyazaki, M., Jinde, K., Koji, T., Yagame, M., Endoh, M., Nomoto, Y. and Sakai, H., 1997. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney International, 52(1), 111-119, https://doi.org/10.1038/ki.1997.310.
Pawlak, K., Pawlak, D. and Mysliwiec, M., 2005. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress. Cytokine, 31(1), 18-24, https://doi.org/10.1016/j.cyto.2004.12.020.
Chonchol, M. and Scragg, R., 2007. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the third national health and nutrition examination survey. Kidney International, 71(2), 134-139, https://doi.org/10.1038/sj.ki.5002002.
Landau, M., Kurella-Tamura, M., Shlipak, M.G., Kanaya, A., Strotmeyer, E., Koster, A., Satterfield, S., Simsonick, E.M., Goodpaster, B., Newman, A.B. and Fried, L.F., 2011. Correlates of insulin resistance in older individuals with and without kidney disease. Nephrology Dialysis Transplantation, 26(9), 2814-2819, https://doi.org/10.1093/ndt/gfq817.